Name | Number of supported studies | Average coverage | |
---|---|---|---|
basal cell | 10 studies | 29% ± 8% | |
epithelial cell | 8 studies | 36% ± 14% | |
alveolar macrophage | 6 studies | 28% ± 8% | |
oligodendrocyte | 6 studies | 22% ± 7% | |
fibroblast | 6 studies | 29% ± 15% | |
squamous epithelial cell | 4 studies | 30% ± 22% | |
secretory cell | 4 studies | 38% ± 20% | |
macrophage | 3 studies | 35% ± 16% | |
type I pneumocyte | 3 studies | 20% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 3 studies | 26% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
uterus | 100% | 3646.02 | 170 / 170 | 98% | 111.18 | 448 / 459 |
thymus | 97% | 2522.03 | 633 / 653 | 99% | 95.36 | 600 / 605 |
skin | 100% | 5086.03 | 1809 / 1809 | 95% | 141.08 | 448 / 472 |
prostate | 100% | 5230.60 | 245 / 245 | 92% | 37.20 | 461 / 502 |
lung | 99% | 3220.02 | 570 / 578 | 93% | 69.22 | 1070 / 1155 |
bladder | 100% | 5746.43 | 21 / 21 | 91% | 110.11 | 457 / 504 |
breast | 100% | 8707.38 | 458 / 459 | 89% | 50.09 | 996 / 1118 |
adrenal gland | 95% | 2104.55 | 244 / 258 | 94% | 52.88 | 216 / 230 |
ovary | 86% | 1557.69 | 154 / 180 | 96% | 77.35 | 411 / 430 |
brain | 92% | 2624.29 | 2437 / 2642 | 88% | 47.86 | 623 / 705 |
esophagus | 100% | 5675.78 | 1445 / 1445 | 78% | 45.87 | 142 / 183 |
intestine | 86% | 5890.19 | 830 / 966 | 70% | 30.03 | 367 / 527 |
stomach | 75% | 2012.51 | 270 / 359 | 71% | 30.79 | 203 / 286 |
kidney | 54% | 967.19 | 48 / 89 | 91% | 56.36 | 819 / 901 |
pancreas | 47% | 684.17 | 154 / 328 | 97% | 97.38 | 173 / 178 |
adipose | 100% | 10037.22 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 78.49 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 197.98 | 1 / 1 |
blood vessel | 100% | 4396.93 | 1330 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 109.24 | 44 / 45 |
muscle | 94% | 3027.11 | 753 / 803 | 0% | 0 | 0 / 0 |
heart | 90% | 1827.44 | 773 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 52% | 22.95 | 15 / 29 |
liver | 4% | 45.59 | 8 / 226 | 43% | 21.64 | 174 / 406 |
spleen | 29% | 376.06 | 70 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 15% | 264.02 | 143 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042771 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0051898 | Biological process | negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0009653 | Biological process | anatomical structure morphogenesis |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0080025 | Molecular function | phosphatidylinositol-3,5-bisphosphate binding |
GO_0005547 | Molecular function | phosphatidylinositol-3,4,5-trisphosphate binding |
GO_0005546 | Molecular function | phosphatidylinositol-4,5-bisphosphate binding |
GO_0010314 | Molecular function | phosphatidylinositol-5-phosphate binding |
GO_0032266 | Molecular function | phosphatidylinositol-3-phosphate binding |
GO_0043325 | Molecular function | phosphatidylinositol-3,4-bisphosphate binding |
Gene name | PHLDA3 |
Protein name | Pleckstrin homology-like domain family A member 3 (TDAG51/Ipl homolog 1) |
Synonyms | TIH1 |
Description | FUNCTION: p53/TP53-regulated repressor of Akt/AKT1 signaling. Represses AKT1 by preventing AKT1-binding to membrane lipids, thereby inhibiting AKT1 translocation to the cellular membrane and activation. Contributes to p53/TP53-dependent apoptosis by repressing AKT1 activity. Its direct transcription regulation by p53/TP53 may explain how p53/TP53 can negatively regulate AKT1. May act as a tumor suppressor. . |
Accessions | ENST00000367311.5 ENST00000367309.1 Q9Y5J5 |